Cardiovascular and mortality benefits of sodium –glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium –glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this ...

Source: Cardiovascular Diabetology - July 9, 2021 Category: Cardiology Authors: Jordi Real, Bogdan Vlacho, Emilio Ortega, Joan Antoni Vall és, Manel Mata-Cases, Esmeralda Castelblanco, Eric T. Wittbrodt, Peter Fenici, Mikhail Kosiborod, Dídac Mauricio and Josep Franch-Nadal Tags: Original investigation Source Type: research